Revenue
2020
2021
2022
2023
2024
Petros Pharmaceuticals, Inc. (PTPI)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2024
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | $5.1M | $5.8M | $6.0M | $7.8M | $9.6M |
| Gross profit | — | $3.9M | $4.2M | $3.7M | $6.2M | $5.5M |
| Research & development | — | $2.6M | $2.4M | $1.7M | $1.8M | $459,636 |
| Operating expenses | $4.6M | $4.6M | $17.8M | $23.6M | $24.3M | $22.8M |
| Operating income | −$4.6M | −$4.6M | −$13.6M | −$19.9M | −$18.0M | −$17.3M |
| EBITDAderived | — | −$1.8M | −$10.3M | −$14.3M | −$11.2M | −$10.6M |
| Net income | $1.9M | −$14.3M | −$8.2M | −$20.0M | −$9.0M | −$20.6M |
| Basic EPSper diluted share | -$1.56 | -$83.47 | -$6.35 | -$9.68 | -$8.25 | -$3.85 |
| Diluted EPSper diluted share | -$1.56 | -$83.47 | -$6.35 | -$9.68 | -$8.25 | -$3.85 |